Last update Aug. 7, 2019

エルトロンボパグ オラミン

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

A thrombopoietin receptor agonist that increases platelet production. Indicated in the treatment of immune thrombopenic purpura, severe aplastic anemia and hepatitis C.
Administered orally once a day.

Since the last update we have not found published data on its excretion in breastmilk.

Its pharmacokinetic data (high percentage of protein binding and very low pKa) makes transfer to milk in significant amounts unlikely.

Its low oral bioavailability impedes transfer from breastmilk to infant plasma, except in premature infants and the immediate neonatal period when there may be greater intestinal permeability.

In addition, eltrombopag forms chelates with polyvalent ions such as calcium, which significantly reduces the drug’s possible absorption by the infant (EMA 2015)

Its use is authorized in Pediatrics from one year of age (EMA 2015).

Alternatives

We do not have alternatives for エルトロンボパグ オラミン.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

エルトロンボパグ オラミン is Eltrombopag in Japanese.

Is written in other languages:

エルトロンボパグ オラミン is also known as

Group

エルトロンボパグ オラミン belongs to this group or family:

Tradenames

Main tradenames from several countries containing エルトロンボパグ オラミン in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 52 %
Molecular weight 443 daltons
Protein Binding 99.9 %
pKa 3.99 -
Tmax 2 - 6 hours
26 - 35 hours

References

  1. EMA. Eltrombopag. Drug Summary. 2015 Full text (in our servers)
  2. EMA. Eltrombopag. Ficha técnica. 2015 Full text (in our servers)

Total visits

1,509

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM